BERLIN, Germany and BRUSSELS, Belgium, December 09, 2025 / Biotech Newswire / --

德国柏林和比利时布鲁塞尔，2025年12月9日 /生物技术新闻社/ --

ProBioGen

普罗维登生物科技公司

and Spica Therapeutics (Spica), a pioneering biotechnology company advancing pathogenic macrophage subset-targeted immunotherapies, today announced a new collaboration. Under the agreement, ProBioGen will perform cell line development for ST101, Spica’s first clinical development candidate anti-CD163 depleting antibody for oncology.

Spica Therapeutics（Spica）是一家开发生物技术公司，致力于推进针对致病性巨噬细胞亚群的免疫疗法，今天宣布了一项新的合作。根据协议，ProBioGen将为Spica的首个临床开发候选药物ST101进行细胞系开发，ST101是一种用于肿瘤学的抗CD163清除抗体。

ST101 is a first-in-class monoclonal antibody designed to selectively deplete immunosuppressive CD163+ tumor-associated macrophages (TAMs). Spica has integrated ProBioGen’s proprietary .

ST101是一种首创的单克隆抗体，旨在选择性清除免疫抑制性的CD163+肿瘤相关巨噬细胞（TAMs）。Spica已整合了ProBioGen的专有技术。

GlymaxX®GlymaxX®

甘露聚糖酶®甘露聚糖酶®

technology to boost antibody-dependent cell-mediated cytotoxicity (ADCC).

技术以增强抗体依赖的细胞介导的细胞毒性（ADCC）。

'We are glad to collaborate with Spica Therapeutics on cell line development for ST101. ProBioGen’s CHO.RiGHT® expression platform including our proprietary DirectedLuck® transposase system for precise genetic engineering is designed to support biologics with high performance, high purity, and robust productivity.

“我们很高兴与Spica Therapeutics在ST101的细胞系开发上进行合作。ProBioGen的CHO.RiGHT®表达平台，包括我们专有的DirectedLuck®转座酶系统用于精准基因工程，旨在支持具有高性能、高纯度和强大生产力的生物制品。”

Incorporating GlymaxX offers an additional layer of functional enhancement aimed at strengthening the therapeutic potential of ST101', s.

结合GlymaxX提供了另一层功能增强，旨在加强ST101的治疗潜力。

aid Dr. Gabriele Schneider, Chief Business Officer at ProBioGen.

援助普罗维登首席商务官加布里埃勒·施耐德博士。

Dr. Hilde Revets, Director of Non-Clinical Development at Spica Therapeutics said:

斯皮卡治疗公司的非临床开发总监希尔德·雷维茨博士说：

'This agreement marks an important step for our development candidate ST101. ProBioGen’s technical and scientific expertise as well as their highly collaborative approach make them a strong partner. Integrating their GlymaxX® technology supports our strategy of developing ST101 to deeply deplete immunosuppressive TAMs to remodel the tumor microenvironment, with the aim of boosting responses of cancer patients receiving immunotherapy.'.

“该协议标志着我们开发候选药物ST101的重要一步。ProBioGen的技术和科学专业知识以及他们高度协作的方式使他们成为强大的合作伙伴。整合他们的GlymaxX®技术有助于我们开发ST101的战略，以深度减少免疫抑制性TAMs，重塑肿瘤微环境，旨在增强接受免疫治疗的癌症患者的反应。”

This collaboration combines Spica’s innovative macrophage-focused therapeutic approach with ProBioGen’s proven expertise in cell line development and enabling innovative technologies. Together, the partnership provides a strong foundation for advancing ST101 towards future development milestones.

此次合作结合了Spica创新的巨噬细胞聚焦治疗方法与ProBioGen在细胞系开发和赋能创新技术方面的成熟专长。通过合作，双方为推动ST101迈向未来的开发里程碑奠定了坚实的基础。

For high resolution please click the image.

请单击图像以获得高分辨率。

Semantic keywords: Manufacturing and Industrial Facilities; International Cooperation; Cell Line; Cell Line Development; Cell Proliferation; Cell Culture Techniques; Culture Media; Recombinant Proteins; Biological Assay; Productivity; Antibody-Dependent Cell Cytotoxicity; Fucose; Glycosylation; Licensure; Germany; ProBioGen, Spica Therapeutics, GlymaxX, ST101, anti-CD163 antibody, CD163+, tumor-associated macrophages, pathogenic macrophage subsets, antibody-dependent cell-mediated cytotoxicity, ADCC, CHO.RiGHT, DirectedLuck, transposase system, genetic engineering, therapeutic potential, tumor microenvironment, immunotherapy, macrophage-focused therapy, afucosylation.

语义关键词：制造和工业设施；国际合作；细胞系；细胞系开发；细胞增殖；细胞培养技术；培养基；重组蛋白；生物测定；生产力；抗体依赖性细胞毒性；岩藻糖；糖基化；许可；德国；ProBioGen，Spica Therapeutics，GlymaxX，ST101，抗CD163抗体，CD163+，肿瘤相关巨噬细胞，致病性巨噬细胞亚群，抗体依赖性细胞介导的细胞毒性，ADCC，CHO.RiGHT，DirectedLuck，转座酶系统，基因工程，治疗潜力，肿瘤微环境，免疫治疗，巨噬细胞靶向治疗，去岩藻糖基化。

About

关于

GlymaxX

GlymaxX

GlymaxX is ProBioGen’s technology for enhancing antibody-dependent cellular cytotoxicity (ADCC) through targeted afucosylation, thereby significantly increasing its activity. GlymaxX is uniquely flexible: It can be integrated into both new and existing antibody cell lines as well as into entire expression and discovery platforms—without affecting productivity or product quality.

GlymaxX 是 ProBioGen 用于通过定向去岩藻糖基化来增强抗体依赖性细胞毒性 (ADCC) 的技术，从而显著提高其活性。GlymaxX 具有独特的灵活性：它既可以整合到新的和现有的抗体细胞系中，也可以整合到整个表达和发现平台中，而不会影响生产效率或产品质量。

Furthermore, the same GlymaxX cell line can produce antibodies with different fucosylation levels simply by changing the culture medium - fully afucosylated in fucose-free conditions or fully fucosylated in fucose-containing medium. This enables the production of multiple product formats—including ADCC-enhanced antibodies, fully fucosylated mAbs, or tailored glycoprofiles for biosimilars.

此外，相同的GlymaxX细胞系只需通过改变培养基，就可以生产具有不同岩藻糖基化水平的抗体——在无岩藻糖条件下完全无岩藻糖基化，或在含岩藻糖培养基中完全岩藻糖基化。这使得多种产品形式的生产成为可能——包括ADCC增强型抗体、完全岩藻糖基化的单克隆抗体，或为生物类似物定制的糖基化谱。

ProBioGen offers GlymaxX royalty-free and non-exclusively as a service or standalone license..

ProBioGen 以服务或独立许可的形式提供 GlymaxX，且免收特许权使用费，并非独家授权。

About

关于

DirectedLuck

定向运气

DirectedLuck is ProBioGen’s next-generation transposase system, combining a highly active transposase/transposon pair with epigenetic targeting to insert multiple transgene copies into genomic regions with high transcriptional activity. This enables exceptionally high and stable protein expression in pools and clones, reducing timelines and manual clone selection efforts.

DirectedLuck 是 ProBioGen 的下一代转座酶系统，结合了高活性的转座酶/转座子对与表观遗传靶向技术，可将多个转基因拷贝插入具有高转录活性的基因组区域。这使得在细胞池和克隆中实现极高且稳定的蛋白表达成为可能，同时缩短时间并减少人工克隆筛选的工作量。

The system is compatible with standard vector designs and diverse host cell lines. DirectedLuck delivers superior cell lines for mAbs, complex glycoproteins, and multi-specific antibody formats. The system is available for out-licensing and is routinely used in ProBioGen’s client projects at no additional charge..

该系统兼容标准载体设计和多样化的宿主细胞系。DirectedLuck 可为单克隆抗体、复杂糖蛋白和多特异性抗体形式提供卓越的细胞系。该系统可供授权使用，并且在 ProBioGen 的客户项目中常规使用，无需额外费用。

About Spica Therapeutics

关于Spica Therapeutics

Spica Therapeutics is a biotechnology company dedicated to transforming the treatment of cancer, fibrosis and inflammatory diseases through precision targeting macrophage biology. Founded on pioneering research from Aarhus University, the company utilizes a proprietary functional fingerprinting platform to identify and deplete specific pathogenic macrophage subsets while preserving beneficial immune cells.

Spica Therapeutics是一家生物技术公司，致力于通过精准靶向巨噬细胞生物学来变革癌症、纤维化和炎症性疾病的治疗。公司基于奥胡斯大学的开创性研究，利用专有的功能性指纹平台识别并清除特定的致病巨噬细胞亚群，同时保留有益的免疫细胞。

Headquartered in Antwerp, Belgium, Spica is backed by a syndicate of leading life science investors. .

总部位于比利时安特卫普的Spica公司得到了一个由领先的生命科学投资者组成的财团的支持。

About

关于

ProBioGen

普罗维登生物科技公司

ProBioGen is a Berlin-based expert in the development and manufacturing of biopharmaceuticals, viral vectors, and vaccines, powered by proprietary technologies that enhance product quality and features. Its

ProBioGen是一家总部位于柏林的生物制药、病毒载体和疫苗开发与生产领域的专家，依托提升产品质量和特性的专有技术。其

CHO.RiGHT®

CHO.RiGHT®

platform enables fast, integrated cell line and process development, comprehensive analytics, and reliable GMP-compliant manufacturing, all supported by a highly experienced team. Operating for over 30 years, ProBioGen runs three manufacturing lines in Berlin, where 300 employees contribute to advancing next-generation therapies and global biotech innovation.

该平台能够快速、整合地进行细胞系和工艺开发、全面分析以及可靠的符合GMP标准的生产，所有这些都由经验丰富的团队提供支持。ProBioGen运营已超过30年，在柏林拥有三条生产线，300名员工致力于推动下一代疗法和全球生物技术创新。

The company’s growth strategy focuses on expanding its service value chain through organic growth and strategic opportunities, with a clear mission to enable tomorrow’s biopharmaceuticals..

公司的发展战略侧重于通过自然增长和战略机遇扩展其服务价值链，其明确使命是助力明天的生物制药。

For more information about ProBioGen, follow us on

欲了解有关ProBioGen的更多信息，请关注我们

LinkedIn

领英

.

。

Contacts

联系人

ProBioGen

ProBioGen

Dr. Gabriele Schneider

葛布丽埃勒·施耐德博士

Chief Business Officer

首席商务官

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

ProBioGen Press Contact

ProBioGen 媒体联系人

Sarah Wandrey

萨拉·万德雷

Senior Communications Manager

高级传播经理

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

Spica

织女星

Dr. Hilde Revets

希尔德·雷维茨博士

Director Non-Clinical Development

非临床开发总监

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

Source: Biotech Newswire

来源：生物技术新闻社